252 related articles for article (PubMed ID: 33352665)
21. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
Liang H; Song X; Zhang Y; Zhang S; Li F; Fang J; Li J; Liang L; Nie L; Ma K; Zhang L; Wang X; Xu J; Wei Y; Wang J; Song Q; Tian G; Mu Y; Gu Y; Yang L; Sun P; Zhong W; Zhao J; Xu Y; Chen M; Wang M
Thorac Cancer; 2019 Jul; 10(7):1521-1532. PubMed ID: 31144459
[TBL] [Abstract][Full Text] [Related]
22. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneous tumor-immune microenvironments between primary and metastatic carcinoid tumors differentially respond to anti-PD-L1 antibody therapy.
Sakata S; Imamura K; Tajima Y; Masuda Y; Sato R; Yoshida C; Okamoto S; Saeki S; Tomita Y; Sakagami T
Thorac Cancer; 2021 Feb; 12(3):397-401. PubMed ID: 33300302
[TBL] [Abstract][Full Text] [Related]
24. Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions.
Fan J; Dai X; Wang Z; Huang B; Shi H; Luo D; Zhang J; Cai W; Nie X; Hirsch FR
Clin Lung Cancer; 2019 Jul; 20(4):e517-e530. PubMed ID: 31138506
[TBL] [Abstract][Full Text] [Related]
25. Tumor-infiltrating CD8
Zeng C; Gao Y; Xiong J; Lu J; Yang J; Wang X; Cai Y; Li L; Fu X
Lung Cancer; 2020 Dec; 150():139-144. PubMed ID: 33142232
[TBL] [Abstract][Full Text] [Related]
26. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
27. Anaplastic Lymphoma Kinase (ALK) Rearrangement-positive Lung Cancer with Transformation to Pleomorphic Carcinoma.
Kamide Y; Kaira K; Watanabe T; Kuribayashi S; Ozawa A; Koga Y; Ono A; Sunaga N; Hisada T; Oyama T; Yamada M
Intern Med; 2015; 54(22):2905-9. PubMed ID: 26568007
[TBL] [Abstract][Full Text] [Related]
28. ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma.
Bi R; Bai Q; Zhu X; Tu X; Cai X; Jiang W; Xu X; Tang S; Ge H; Chang B; Cheng Y; Gan H; Zhou X; Yang W
Diagn Pathol; 2019 Aug; 14(1):96. PubMed ID: 31455365
[TBL] [Abstract][Full Text] [Related]
29. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
[TBL] [Abstract][Full Text] [Related]
30. Targeting ALK in Neuroendocrine Tumors of the Lung.
Akhoundova D; Haberecker M; Fritsch R; Höller S; Kiessling MK; Rechsteiner M; Rüschoff JH; Curioni-Fontecedro A
Front Oncol; 2022; 12():911294. PubMed ID: 35756632
[TBL] [Abstract][Full Text] [Related]
31. PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.
Li T; Zhang F; Wu Z; Cui L; Zhao X; Wang J; Hu Y
Lung Cancer; 2020 Jan; 139():146-150. PubMed ID: 31794921
[TBL] [Abstract][Full Text] [Related]
32. Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report.
Fan J; Wu J; Huang B; Zhu Y; Shi H; Dai X; Nie X
Diagn Pathol; 2020 May; 15(1):42. PubMed ID: 32375829
[TBL] [Abstract][Full Text] [Related]
33. Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma.
Yin K; Feng HB; Li LL; Chen Y; Xie Z; Lv ZY; Guo WB; Lu DX; Yang XN; Yan WQ; Wu YL; Zhang XC
Thorac Cancer; 2020 Feb; 11(2):346-352. PubMed ID: 31794146
[TBL] [Abstract][Full Text] [Related]
34. A Rare Fusion of CLIP1 and ALK in a Case of Non-Small-Cell Lung Cancer With Neuroendocrine Features.
Pinsolle J; Mondet J; Duruisseaux M; d'Alnoncourt S; Magnat N; de Fraipont F; Moro-Sibilot D; Toffart AC; Brambilla E; McLeer-Florin A
Clin Lung Cancer; 2019 Sep; 20(5):e535-e540. PubMed ID: 31171381
[No Abstract] [Full Text] [Related]
35. ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases.
Fares AF; Lok BH; Zhang T; Cabanero M; Lau SCM; Stockley T; Patel D; Bradbury PA; Sacher A; Yasufuku K; Morash BA; Sabatini PJB; Nguyen LN; Leighl NB; Tsao MS; Shepherd FA; Liu G; Martins-Filho SN; Pal P
Lung Cancer; 2020 Aug; 146():350-354. PubMed ID: 32546380
[No Abstract] [Full Text] [Related]
36. Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells?
Zhou F; Hou L; Ding T; Song Q; Chen X; Su C; Li W; Gao G; Ren S; Wu F; Fan J; Wu C; Zhang J; Zhou C
Lung Cancer; 2018 Feb; 116():30-37. PubMed ID: 29413048
[TBL] [Abstract][Full Text] [Related]
37. Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study.
El Yacoubi H; Sow ML; Kettani F; Gamra L; Mestari A; Jabri L; Elghissassi I; Errihani H
BMC Cancer; 2020 May; 20(1):479. PubMed ID: 32460789
[TBL] [Abstract][Full Text] [Related]
38. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
39. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
[TBL] [Abstract][Full Text] [Related]
40. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
Descourt R; Perol M; Rousseau-Bussac G; Planchard D; Mennecier B; Wislez M; Cortot A; Guisier F; Galland L; Dô P; Schott R; Dansin E; Arrondeau J; Auliac JB; Chouaid C
Lung Cancer; 2019 Oct; 136():109-114. PubMed ID: 31491676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
